Enlivex wins Israeli patent for Allocetra osteoarthritis use

Enlivex Therapeutics Ltd. reported that it has received an Israeli patent covering methods of using its Allocetra™ therapy to treat osteoarthritis.

Accepted by SEC EDGAR 09/09/2025 - 08:05 AM EDT

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

6-K

Rhea-AI Filing Summary

Enlivex Therapeutics Ltd. reported that it has received an Israeli patent covering methods of using its Allocetra™ therapy to treat osteoarthritis. The patent extends Enlivex’s intellectual property protection in Israel through at least 2040, strengthening the company’s legal protection around this specific therapeutic use.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Enlivex Therapeutics (ENLV) announce in this Form 6-K?

Enlivex Therapeutics announced the issuance of an Israeli patent covering methods of using Allocetra™ to treat osteoarthritis. The patent provides added intellectual property protection in Israel through at least 2040, potentially reinforcing exclusivity around this therapeutic approach in that market.

What does the new Israeli patent cover for Enlivex Therapeutics (ENLV)?

The new Israeli patent covers methods of using Allocetra™ to treat subjects with osteoarthritis. This means specific treatment approaches using Allocetra™ for osteoarthritis are now protected, giving Enlivex formal rights over these claimed medical uses in Israel.

How long will Enlivex’s new Israeli patent protect Allocetra™ in osteoarthritis?

The patent will provide Enlivex with added intellectual property protection in Israel through at least 2040. This long-dated protection helps secure the company’s exclusive rights to the claimed Allocetra™ osteoarthritis treatment methods during that period.

Where did Enlivex Therapeutics (ENLV) obtain new intellectual property protection?

Enlivex obtained new intellectual property protection in Israel through the issuance of a national patent. The patent protects methods of using Allocetra™ to treat osteoarthritis, giving the company enforceable rights within the Israeli jurisdiction through at least 2040.

What is Allocetra™ in the context of Enlivex Therapeutics’ new patent?

Allocetra™ is the therapy at the center of Enlivex’s new Israeli patent. The patent specifically covers methods of using Allocetra™ to treat osteoarthritis, indicating that Enlivex is securing legal protection around this particular clinical application of its technology in Israel.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of: September 2025

Commission file number: 001-36578

ENLIVEX THERAPEUTICS LTD.

(Translation of registrant’s name into English)

14 Einstein Street, Nes Ziona, Israel 7403618

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

On September 9, 2025, Enlivex Therapeutics Ltd., a company organized under the laws of the State of Israel (“Enlivex”), issued a press release announcing the issuance of an Israeli patent that will provide Enlivex with added intellectual property protection in Israel through at least 2040 with claims covering methods of using Allocetra™ to treat subjects with osteoarthritis. A copy of such press release is furnished as Exhibit 99.1 to this Report on Form 6-K and incorporated herein by reference.

Exhibit No.

99.1		Press Release issued by Enlivex Therapeutics Ltd. on September 9, 2025.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Enlivex Therapeutics Ltd.
	(Registrant)

	By:	/s/ Oren Hershkovitz
	Name:	Oren Hershkovitz
	Title:	Chief Executive Officer

Date: September 9, 2025

Source: View Original Filing on SEC EDGAR